A multistep platform identifies spleen-tropic lipid nanoparticles for in vivo T cell–targeted delivery of gene-editing proteins
Science Advances · 24.10.2025 · 11 (43)
DOI: 10.1126/sciadv.ady5579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 24.10.2025. Verfasst von Xiaoya Lu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Gene Editing, Spleen, T-Lymphocytes, Nanoparticles. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) are a promising nonviral delivery system for gene-editing proteins, but optimal formulations remain underexplored. Unlike messenger RNA–based approaches, ribonucleoprotein delivery enables immediate genome editing without relying on endogenous translation. However, intracellular delivery remains a major challenge due to protein size, charge variability, and susceptibility to denaturation and degradation. Here, we present a multistep screening platform to optimize LNP formulations for gene-editing protein delivery, focusing on in vivo T cell targeting. Through in vitro screening of a composition library, we identified top-performing candidates. In vivo screening in Ai9 mice revealed a spleen-tropic LNP formulation that preferentially targets T cells, enabling efficient gene editing in vivo. Using this LNP formulation, we achieved targeted knockout of CCR5 and PD-1 in splenic T cells, supporting potential applications in HIV resistance and cancer immunotherapy. Furthermore, a machine learning–guided mechanistic study revealed key design principles for LNP-based protein delivery, highlighting unexplored opportunities for in vivo genome-editing therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
- Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD, USA.
- Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
ORCID-Profile: Xiaoya Lu, Yining Zhu, Christine Wei, Leonardo Cheng, Kailei D Goodier, Jiayuan Kong, Xiangyu Gao, Di Yu, Xiang Liu, Yuanmuhuang Long, Jinghan Lin, Hai-Quan Mao
Förderung
- NIBIB NIH HHS
- NCI NIH HHS
Zitieren
APA
Lu, X., Zhu, Y., Wei, C., Cheng, L., Goodier, K. D., Kong, J., Gao, X., Yu, D., Liu, X., Long, Y., Lin, J., Ma, J., Su, Y., & Mao, H. Q. (2025). A multistep platform identifies spleen-tropic lipid nanoparticles for in vivo T cell–targeted delivery of gene-editing proteins. Science Advances, 11(43). https://doi.org/10.1126/sciadv.ady5579
Vancouver
Lu X, Zhu Y, Wei C, Cheng L, Goodier KD, Kong J, et al. A multistep platform identifies spleen-tropic lipid nanoparticles for in vivo T cell–targeted delivery of gene-editing proteins. Science Advances. 2025;11(43). doi:10.1126/sciadv.ady5579
BibTeX
@article{Lu2025,
author = {Lu, Xiaoya and Zhu, Yining and Wei, Christine and Cheng, Leonardo and Goodier, Kailei D and Kong, Jiayuan and Gao, Xiangyu and Yu, Di and Liu, Xiang and Long, Yuanmuhuang and Lin, Jinghan and Ma, Jingyao and Su, Yunhe and Mao, Hai-Quan},
title = {A multistep platform identifies spleen-tropic lipid nanoparticles for in vivo T cell–targeted delivery of gene-editing proteins},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {43},
doi = {10.1126/sciadv.ady5579}
}
EUVIMED